Hostname: page-component-745bb68f8f-mzp66 Total loading time: 0 Render date: 2025-01-09T12:23:04.172Z Has data issue: false hasContentIssue false
  • English
  • Français

PspA family typing and PCR-based DNA fingerprinting with BOX A1R primer of pneumococci from the blood of patients in the USA with and without sickle cell disease

Published online by Cambridge University Press:  04 October 2004

D. B. PAYNE ,
A. SUN ,
J. C. BUTLER ,
S. P. SINGH ,
S. K. HOLLINGSHEAD  and
D. E. BRILES
D. B. PAYNE
Affiliation:
Biomedical Research and Training Programs, Alabama State University, Montgomery, AL, USA
A. SUN
Affiliation:
Biomedical Research and Training Programs, Alabama State University, Montgomery, AL, USA
J. C. BUTLER
Affiliation:
National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
S. P. SINGH
Affiliation:
Biomedical Research and Training Programs, Alabama State University, Montgomery, AL, USA
S. K. HOLLINGSHEAD
Affiliation:
Department of Microbiology, University of Alabama in Birmingham, Birmingham, AL, USA
D. E. BRILES
Affiliation:
Department of Microbiology, University of Alabama in Birmingham, Birmingham, AL, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Disease and mortality rates for Streptococcus pneumoniae infections are much higher in patients with sickle cell disease (SCD) than in age-matched patients without SCD. Pneumococcal surface protein A (PspA) has been proposed as a component in human vaccines against S. pneumoniae to provide greater breadth of coverage than can be obtained with the 7-valent conjugate vaccine. The cross-reactivity of PspA is associated with the ‘PspA family’ structure. In this study we examined strains of S. pneumoniae from patients with and without SCD to determine whether the strains infecting the hypersusceptible population of SCD patients were limited to the same two PspA families already known to comprise over 95% of strains infecting non-SCD patients. Each strain was also evaluated according to the presence or absence of specific PCR fragments based on repetitive BOX elements to screen for possible SCD-associated clonal structure. Strains from SCD and non-SCD patients were similarly dispersed among the most common BOX PCR groups and strains from both groups expressed a similar distribution of PspA variants. Thus, a PspA vaccine designed for the population at large should also be appropriate for patients with SCD.

Type
Research Article
Information
Epidemiology & Infection , Volume 133 , Issue 1 , February 2005 , pp. 173 - 178
Copyright
2004 Cambridge University Press